Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 95
Selected: 0
NCT IDTitle
NCT03773510Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin
NCT00796120An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)
NCT01299636Study of PM060184 in Patients With Advanced Solid Tumors
NCT06524583Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
NCT02163720Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)
NCT02809339Improving Quality of Care for Patients With Recurrent Ovarian Cancer
NCT05063318Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
NCT03070964A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
NCT00050414A Study of Trabectedin in Patients With Advanced Ovarian Cancer
NCT00404521A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors
NCT02204111Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma
NCT01876043Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial
NCT05121740Extension Study in a Cohort of Adult Patients With COVID-19 Infection
NCT01970540Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
NCT04382066Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19
NCT02398058Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)
NCT02533674Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
NCT05705167Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)
NCT00113607An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer
NCT05572476Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer
NCT05072106Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
NCT03164980QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer
NCT02825420Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients
NCT01970553Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors
NCT05076396PM14 Administered Intravenously to Patients with Advanced Solid Tumors
NCT06050434Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients
NCT00780975A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
NCT01222767Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy
NCT06088290Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
NCT00027508Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma
NCT02566993Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
NCT01379989INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer
NCT04383119Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
NCT03838744Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.
NCT02367924Efficacy and Safety of Trabectedin (Yondelis®) in Patients With Advanced Soft Tissue Sarcoma
NCT01735071Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer
NCT01149681Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
NCT03427268Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
NCT01314599Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome
NCT01980667Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors
NCT01273493A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
NCT02100657Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
NCT00786838A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
NCT00780143Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia
NCT01102426Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
NCT03117361Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
NCT04358237Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.
NCT02805725Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide
NCT01343277A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
NCT00788099Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas